RENATO PATIAG: Open Payments
NPI 1093373334 · BURBANK, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,923 in 82 payments from 25 companies in 2025. Trend: 2023 $1,360 · 2024 $1,757 · 2025 $1,923
Food & beverage: $1,923
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 24 | $373 |
| Ferring Pharmaceuticals Inc. | 12 | $188 |
| PFIZER INC. | 6 | $170 |
| Teleflex LLC | 4 | $166 |
| Janssen Biotech, Inc. | 4 | $162 |
| Astellas Pharma US Inc | 2 | $118 |
| PROGENICS PHARMACEUTICALS, INC. | 4 | $110 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $59 |
| 180 Medical, Inc. | 2 | $56 |
| Antares Pharma, Inc. | 2 | $49 |
Products named: ADSTILADRIN, GEMTESA, ORGOVYX, XTANDI, BARRIGEL, LORBRENA, PYLARIFY, ERLEADA.
Industry payments across CA — which companies pay providers there.
